Brian Hilberdink Becomes New U.S. Pharma Head at Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc. has announced the appointment of Brian Hilberdink as the new President of U.S. Human Pharma. This strategic move comes at a crucial time as the company is set to expand its current portfolio and push for the launch of new pharmaceutical products. With over 25 years of industry experience, Hilberdink is expected to significantly contribute to Boehringer’s growth and dedication to addressing significant unmet patient needs.

Hilberdink’s previous leadership roles at LEO Pharma and Novo Nordisk have equipped him with invaluable experience in global marketing, general management, and launching blockbuster products, particularly in the areas of obesity and diabetes. His innovative strategies and accomplishments in commercial leadership have made him an ideal fit for Boehringer Ingelheim’s vision to foster a culture of impact and performance. Under his leadership at LEO Pharma, the North American region and U.S. affiliate saw significant growth, spotlighting his capability to drive market success.

Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA Corporation, expressed optimism about this new chapter under Hilberdink’s leadership. This appointment marks a step forward in Boehringer’s mission to revolutionize the pharmaceutical industry and make a lasting impact on patient care. With Hilberdink at the helm, Boehringer is poised for a decade of transformative growth and innovation, enhancing its legacy of making a difference in patients’ lives.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Marcus Chalk today!